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Background: Magnesium level alteration may cause coagulation abnormality resulting in
bleeding complication after off-pump coronary artery bypass grafting. In this study, we
investigated the effect of magnesium on the postoperative coagulation proﬁle and bleeding
in OPCAB patients.
Methods: In a double blind clinical trial, six hundred patients were randomly allocated to two
groups: group A (n = 150) and group B (n = 450). Group A received 50 mg/kg of magnesium
sulfate (MS) in 100 ml 0.9% NaCl solution over 20 min before the anesthesia induction. Group
B or control group received only 100 ml 0.9% NaCl solution at the same time points. OPCAB
was performed with standard technique and device. Blood samples were collected 30 min
before and 6 h after the surgery to analyze hemoglobin and blood coagulation tests.
Postoperative exploration for bleeding, blood transfusion, and volume of transfusion was
recorded. The two groups compared with t-test and x2 tests and p-valve <0.05 were
considered as signiﬁcant.
Results: However, postoperative hemoglobin was statistically lower in group A compared
with group B, but platelet, PT, and aPTT tests were not statistically different between two
groups. The serum MS level, exploration for bleeding, volume of packed cell transfusion, and
volume of postoperative bleeding were statistically different between group A vs group B.
Conclusion: Preoperative MS use may be associated with the postoperative platelet dysfunc-
tion and increased tendency to bleeding. This is an important risk factor for postoperative
bleeding in the OPCAB in absence of CPB use.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Magnesium sulfate (MS) is commonly used in on-pump
cardiac surgery to abolish postoperative arrhythmia such as* Corresponding author.
E-mail address: r.faraji61@gmail.com (R. Faraji).
http://dx.doi.org/10.1016/j.ihj.2015.08.023
0019-4832/# 2015 Cardiological Society of India. Published by Elsevieratrial ﬁbrillation and reperfusion injury. CPB induced hypo-
magnesemia is well known, and its prescription in on-pump
patients seems to be logical. Currently this drug has also been
widely used in OPCAB in case of reperfusion injury prevention,
shortening of operation time, early or fast tract extubation, B.V. All rights reserved.
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intubation time, preventing sudden death, and preventing
coronary artery spasm.2 Briel et al. found that the inhibitory
mechanisms of MS in platelet function revealed as diffuse
bleeding in postoperative period. MS inhibited platelet
aggregation in human platelets.3 Inhibition of phosphoino-
sitole breakdown in platelet granule in dose-dependent
manner related to MS. Platelet aggregation and thrombin
related intracellular calcium transfer in platelets are also
inhibited by MS. Inhibition of platelet aggregation by platelet
aggregation was closely related to its incorporation into
platelets.4 Platelet incorporation of platelet aggregation was
associated with a signiﬁcant reduction in platelet sensitivity
to aggregation by adenosine 50-diphosphate, arachidonic
acid. Platelet incorporation of platelet aggregation inhibited
adenosine 5-phosphate-induced stimulation of platelet
protein kinase C (PKC) as determined by phosphorylation
of the 47-kDa PKC substrate. Platelets derived from these
subjects after supplementation also demonstrated apparent
complete inhibition of PKC stimulation by adenosine phos-
phate.5,6 We studied the effect of intravenous platelet
aggregation infusion on postoperative bleeding in patients
with OPCAB method who continued to take aspirin preoper-
atively. Considering the results of previous studies, the goals
of this study were to compare the postoperative blood loss in
patients not receiving magnesium after OPCAB with the
group who received magnesium and to compare the
requirement of blood, fresh frozen plasma (FFP), and platelet
within 24 h after surgery.
2. Methods
After approval of the hospital ethics committee, this
prospective, randomized, controlled, double blind study
was conducted in our center. After obtaining written,
informed consent, six hundred consecutive adult patients
undergoing elective OPCAB method were prospectively
randomized into two groups using a computer generated
random number. In a double blind clinical trial, six hundred
patients were randomly allocated to two groups: group A
(n = 150) and group B (n = 450). Group A received 50 mg/kg of
MS over 20 min before induction of the anesthesia. Group B or
control group received only 100 ml 0.9% NaCl solution at the
same time points. With an intravenous cannulation, 5 ml
venous blood was withdrawn for the measurement of MS,
hemoglobin, platelet count, prothrombin time (PT), activated
partial thromboplastin time (aPTT), international normalized
ratio (INR), and ﬁbrinogen and activated clotting time (ACT).
The bleeding time (BT) was determined using the Ivy method
before induction of anesthesia. The treatment group received
MS infusion and the control group received an equivalent
amount of saline in a double-blind fashion. The solutions
were prepared by the study co-coordinator, and the anesthe-
tist was blinded to the infused medication. The investigator,
who assessed blood loss and reported the laboratory tests,
was also blinded to group allocation. Patients received MS
infusion after induction of anesthesia. Patients with history of
antiplatelet drugs use, recent thrombolytic therapy, warfarin
therapy, history of previous heart surgery, liver disease, renalfailure, hypersensitivity to MS, emergency cases who under-
went redo operation within course of study were excluded
from the study. Patients with history of ASA using were
included into the study. All patients were premedicated with
midazolam 0.1 mg/kg intravenously and their usual, beta
blocker and calcium channel blocker in the morning orally. In
the operation room arterial line for pulse oximetry, blood
pressure and central venous pressure line, intra esophageal
temperature thermometer monitoring, ECG and arterial blood
gases, serum electrolytes were routinely monitored in all
patients. Anesthesia was induced with fentanyl and mid-
azolam; tracheal intubation was performed with pancuro-
nium. Anesthesia was maintained with oxygen in air 50%
along with isoﬂurane, intermittent bolus of fentanyl and
pancuronium along with infusion of propofol. OPCAB was
performed through a sternotomy incision. Conduits for
OPCAB, including the left internal mammary artery and
saphenous vein were harvested in the standard fashion.
Revascularization on the left anterior descending artery with
the left internal mammary was typically performed ﬁrst,
followed by revascularization of LCX and the right coronary
artery distribution. We used an optimal combination of
pharmacological and mechanical methods to reduce the
coronary artery movement. Intravenous heparin (1 mg/kg)
was given to maintain ACT between 200 and 350 s. Distal
coronary anastomosis was performed using a running 7-0
monoﬁlament viline or proline suture. Proximal anastomosis
to aorta was made on a punch aortotomy after applying a side
clamp to the ascending aorta. Visualization of the anastomo-
sis site was enhanced with the use of humidiﬁed carbon
dioxide blower. Before setting the octopus on the coronary
artery target for bypass grafting, the patient received
amiodarone and esmolol for reduction of heart rate and then
with maintaining a continuous communication with the
anesthesia team, hemodynamic change was monitored and
the cardiac arrhythmia was managed. After surgery the
patient was admitted to the ICU. Serial electrocardiograms
and estimation of serum creatinine phosphokinase and its MB
fraction were done to detect perioperative ischemia. Postop-
erative monitoring also included arterial blood line, pulse
oximetry, central venous pressure line, temperature, ECG and
arterial blood gases, serum electrolytes (Na+, K+, Ca++), urine
output, and volume of mediastinal drainage. Time of surgery
was determined by the investigator and was deﬁned as time
from induction of anesthesia to skin closure. Anesthesia time
was deﬁned from induction to extubation in intensive care
unit. Packed cell blood was transfused when hemoglobin
values dropped below 11 gm%. The amount of mediastinal
drainage was noted for 24 h. Postoperative blood transfusion
was guided with coagulation tests monitoring. Platelet
concentrate was transfused if patient had persistent bleeding
(>200 ml/h for >2 h) despite normality of PT and ACT. FFP was
transfused if PT was prolonged by >17 s. FFP was transfused
if PT was prolonged by >50%. The criteria for re-exploration
of postoperative including (1) more than 500 ml in the
ﬁrst hour of surgery, (2) more than 400 ml during each of
ﬁrst 2 h, (3) more than 300 ml during each of the ﬁrst 3 h, (4)
more than 1000 ml in total during the ﬁrst 4 h, (5) more than
1200 ml in total during the ﬁrst 5 h, and (6) sudden massive
bleeding.
Table 1 – Patient's characteristics and duration of surgery
and anesthesia time values are mean (SD) or number.
Variable Magnesium
(n = 50)
Placebo
(n = 450)
p-value
Age (years) 65  15 68  13 0.664
Sex (male/female) 28/22 250/200 0.342
ASA usage 99% 97% 0.987
Duration of surgery (min) 120  20 110  15 0.530
Duration of anesthesia (min) 8.2  3.4 9.2  4.1 0.791
Inotropic usage 60% 21% 0.043
Postoperative bleeding 650  250 190  90 ml 0.004
Number of grafts 3.9  1.1 3.8  1 0.421
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Sample size was estimated by a pilot study. According to
primary results, prevalence of bleeding as an important
variable in groups A and B was 15% and 5% subsequently,
thus by including ratio of 3 to 1 (because of observed low
prevalence), group sample sizes of 151 in group A and 453 in
group achieve 90% power to detect a difference between,
groups proportion of 0.1. Numerical variables were considered
as mean  SD. Numerical parametric data were compared by
unpaired t-test (independent sample t-test). Categorical data
were compared by x2 test and variables with p-value <0.1 were
entered in logistic regression model and odd ratio of them
obtained. The p-valve <0.05 were considered as signiﬁcant.
3. Results
Patients' demography and duration of surgery, anesthesia and
inotropic drug use are summarized in Table 1. BT, hemoglobin,
platelet count, PT, aPTT, INR, and ﬁbrinogen are shown in
Table 2. There were signiﬁcant differences in the mean (SD)
magnesium concentrations preoperatively, immediately after
operation (0.89 (0.12) and 0.83 (0.12) mmol l1) and 6 h after
surgery (1.02 (0.20) and 0.86 (0.13) mmol l1) in the magnesiumTable 2 – Effect of MS on coagulation parameters after OPCAB 
Magnesium (n = 5) 
BT (s)
Preoperative 245  45 
Immediately postoperative 277  66 
6 h after surgery 288  90 
Platelet count (109 l1)
Preoperative 245  54 
Immediately postoperative 210  63 
6 h after surgery 222  33 
Hemoglobin (g/dl)
Preoperative 13.6  1.2 
Immediately postoperative 10.1  1.1 
6 h after surgery 10.7  1.5 
PT (s)
Preoperative 13.1  0.8 
Immediately postoperative 12.8  1.1 
6 h after surgery 11.9  0.8 
aPTT (s)
Preinduction 25.2  4 
In admission to ICU 243.1 
6 h after surgery 25.1  2.9 
INR
Preinduction 1.021  0.1 
In admission to ICU 1.1  0.2 
6 h after surgery 1.02  0.1 
Fibrinogen (g/dl)
Preinduction 3.02  0.9 
Immediately postoperative 3.3  0.7 
6 h after surgery 2.8  0.5 
ACT (s)
Preinduction 110  11 
Immediately postoperative 115  9 
6 h after surgery 112  13 and saline groups, respectively. The immediate respective
postoperative BT was 277  66 vs 256  46 in magnesium and
placebo groups, respectively. The BT in 6 h of operation was
288  90 vs 243  66 ( p = 0.006). In magnesium and saline
groups, respectively, the immediate postoperative respective
platelet counts were 210  63 vs 214  46 in magnesium and
placebo groups ( p = 0.642). Platelet count in 6 h of operation
was 222  33 vs 234  54 in magnesium and saline groups,
respectively ( p = 0.776). The immediate postoperative HB was
10.7  1.5 vs 13.3  1.6 in magnesium and placebo groups,
respectively ( p = 0.008). The immediate postoperative PT was
12.8  1.1 vs 12.3  0.5 in magnesium and placebo groups,values are mean (SD).
Control (n = 45) p-value
234  67 0.987
256  46 0.049
243  66 0.006
261  45 0.491
214  46 0.642
234  54 0.776
14.1  1.8 NS
13.3  1.6 0.008
12.1  1.5 0.003
12.9  0.5 0.123
12.3  0.5 0.443
12  0.8 0.986
22.7  3 0.219
24.7  1.9 0.044
20.4  1.9 0.010
1.06  0.1 0.491
1.04  0.1 0.654
1.5  0.2 0.049
3.1  1 0.325
3.1  0.6 0.761
3.0  0.4 0.543
115  12 0.067
113  11 0.056
117  14 0.098
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12  0.8. In magnesium and saline groups, respectively
( p = 0.986), the immediate postoperative aPTT was 24 3.1 vs
24.7 1.9 in magnesium and placebo groups, respectively
( p = 0.044). BT in 6 h of operation was 25.1  2.9 vs 20.4  1.9
in magnesium and saline groups, respectively ( p = 0.010). The
immediate postoperative Fibrinogen level was 3.3  0.7 vs 3.1
 0.6 in magnesium and placebo groups, respectively
( p = 0.761). Fibrinogen in 6 h of operation was 2.8  0.5 vs
3.0  0.4, respectively ( p = 0.543). The immediate postopera-
tive INR was 1.1  0.2 vs 1.04  0.1, in magnesium and placebo
groups, respectively ( p = 0.654). INR in 6 h of operation was
1.02  0.1 vs 1.5  0.2 in magnesium and saline groups,
respectively ( p = 0.049). The mean (SD) blood loss was 650
 250 and 190  90 ml in the magnesium and saline groups,
respectively ( p = 0.004). The aPTT in ICU admission and 6 h
after surgery was prolonged in the magnesium group, and the
values were statistically different. The platelet count, PT, and
ﬁbrinogen levels were similar in the two groups at all times
(Table 2). The INR in 6 h of ICU admission was different
between groups. But was not different in immediately
postoperative period. Important source of postoperative
bleeding found at reoperation for bleeding in group A (24
cases) was diffuse bleeding (coagulopathy) in 18 cases and
both surgical and diffuse bleeding in 6 cases. In control group,
of 450 cases, 27 cases of bleeding were detected. Of 27 cases, 21
patients had surgical bleeding due to Lima side branches, LIMA
chest wall bed, LIMA distal anastomosis, proximal and distal
vein grafts, vein side branches, and sternum although other
causes of bleeding were found in four cases and two cases had
diffuse bleeding. If bleeding was excessive and the patient
fulﬁlled criteria of re-exploration, the patient was managed as
follows: (a) with additional dose of protamine if ACT was
longer than 120 s, (b) with 5 units of FFP if the aPTT was >45 s,
and (c) with 8 units of platelet concentrate, if the platelet count
was <80,000  109 l. In group A, except to abnormal aPTT and
BT tests, the other coagulation tests were normal. Excessive
bleeding in group A was treated by FFP and platelets
concentrate. If bleeding continues despite coagulopathy
management and correction of aforementioned tests, redo
operation was performed. In our study, aprotinin and
tranexamic acid were not used, because they have been
questioned too, since the protective mechanism of tranexamic
acid and aprotinin on platelet function is controversial.
4. Discussion
Hypomagnesemia and consequent coronary spasm are a
serious cause of myocardial ischemia, arrhythmia, cardiac
collapse, and death in OPCAB subjects. Hypomagnesemia
may occur intraoperatively or in the immediate postoperative
period of OPCAB on the targeted arteries or on the nontargeted
vessels. However, many factors have been reported as the
etiology of coronary artery spasm, after OPCAB, but hypo-
magnesemia has been considered as a trigger of coronary
spasm.7 Zangrillo et al. reported that an extra cellular MS ion
plays an important role in the regulation of vasomotor tone.
Sudden decrease of extra cellular MS ion resulted in rapid
increase in coronary artery tone, and thus perioperativehypomagnesemia will evoke spasm in OPCAB cases, in which
some vasoactive agents such as ephedrine are routinely used
intraoperatively for stabilization of hemodynamic condition.
Perioperative hypomagnesemia in OPCAB patients has been
attributed mainly to hemodilution caused by nonMS contain-
ing crystalloid solution and renal loss by diuretics, intra
cellular transfer of MS, metabolic response to surgical trauma
and to the pain.8 One study showed that hypomagnesemia
occurred in 89% of cases with OPCAB, and that was much
higher than that reported by Maslow (35%).9,10 Native and
bypassed coronary arteries and grafts are highly sensitive to
spasm due to tendency for perioperative hypomagnesemia
especially in OPCAB. Satoke et al. reported no spasm in
coronary artery in OPCAB patients since they treated with
supplement of MS during their study. Evaluation of serum
level of Mg++ has an important role in guiding magnesium
infusion in the prevention of intraoperative or postoperative
hypomagnesemic complications such as atrial ﬁbrillation,
serious cardiac arrhythmias and postoperative tonic colonic
convulsion. Most of patients with OPCAB have some degree of
congestive heart failure and comorbid diseases, and may have
received diuretics that all of these risk factors predispose to a
hypomagnesemia state.11 We have used MS routinely in all
patients with off-pump surgery who had adequate urine
output. With revealing result of this study, the patients with
risk of Mg deﬁciency and who have established arrhythmia
received Mg.12 Thus although hypomagnesemia may have a
role in the development of postoperative cardiac arrhythmias
and the preoperative infusion of magnesium may reduce the
incidence of serious cardiac arrhythmias after coronary
bypass surgery, but MS by mechanism of dose-dependent
prolongation of BT and inhibition of platelet aggregation, and
ﬁbrinogen binding to the platelet GP IIb/IIIa receptor may lead
to postoperative bleeding. The results of the our study show
that group A (Magnesium Group) patients had a great increase
in the amount of postoperative bleeding observed in the ﬁrst
24 h postoperative period, and packed blood cells require-
ments were also greater than group B patients, and also the
difference was statistically signiﬁcant. Preoperative platelet
function was evaluated by platelet count, PT, and ACT.13 The
postoperative bleeding is a major drawback of CABG. Thus
blood-saving strategy is of great interest to cardiac surgeons
to reduce hospital cost, blood bank consuming reserve,
mediastinitis, allergic reactions, and viral infections. Another
approach for blood-saving strategy is the use of drugs that
with different mechanisms reduce post-CABG bleeding.
Intraoperative aprotinin, Epsilon, and aminocaproic acid
have been used as an antiﬁbrinolytic therapy and as an
important preventive strategy of reducing postoperative
bleeding. These agents prevent ﬁbrinolysis, platelet activa-
tion, prevents activation of plasminogen and plasmin release.
Preoperative use of these drugs in CPB prevents ﬁbrinolysis,
decreases postoperative bleeding, and decreases blood
products requirements. But in the absence of CPB, use of
these drugs is prohibited in off-pump subjects due to
increasing risk of early graft failure, thus although intrave-
nous magnesium infusion may have a logical advantage in
off-pump cases in preventing intra and postoperative risk of
arrhythmia provoked by multiple risk factors. These risk
factors including, temporary occlusion of coronary artery,
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tion, congestive heart failure, and comorbid disease but
increasing risk of bleeding reduce the beneﬁt of aforemen-
tioned measure. It may be concluded from the study that,
however MS may be or has a beneﬁcial effect on preventing
cardiac arrhythmias in the post-off-pump period, but a
signiﬁcant increase in risk of perioperative bleeding and
blood product requirements.14,15 England showed that MS not
only improves graft patency rates after coronary artery
bypass grafting but also caused platelet dysfunction and
increased BT. Inhibition of ADP induced platelet aggregation
was observed in healthy volunteers after administration of
MS.11 Complete inhibition of platelet aggression with high
dose of magnesium was reported, although data on the effect
of MS on p-selectin expression and ﬁbrinogen binding are
limited.16 There are no randomized clinical trials to evaluate
the effects of MS on postoperative bleeding, so it has been
controversy to prescribe MS before surgery.14 Recent studies
about postoperative bleeding have not revealed that outcome
is actually changed in patients who take MS vs those who
discontinue MS before cardiac surgery. Since the beneﬁts of
MS have been clearly demonstrated in reperfusion injury and
ventilation time, but it is not deﬁnitely speciﬁed in post-CPB
bleeding, so it is reasonable to examine the effect of MS in
postoperative bleeding.17 Gries concluded that magnesium
inhibits the platelet function both in vivo and in vitro.
However, this antithrombotic effect of magnesium may be
beneﬁcial in some patients after coronary revascularization,
but magnesium therapy should be carefully considered in
patients with preoperative ASA and antiplatelet drug use,
impaired platelet function and coexisting bleeding disorders.
Whether magnesium exerts an inhibitory effect on platelet
function in patients receiving heparin and aspirin in OPCAB
has not been investigated.13 Platelet dysfunction is the most
important etiologic factor in the hemostatic defect observed
following the heparin usage.18–21 Kynczl-Leisure examined
the effect of MS on the platelet function and ﬁbrinolysis
process when administered before the institution of CPB. Use
of MS resulted in a signiﬁcant prolongation of the BT, a
signiﬁcant reduction in the level of shed blood thromboxane
B2, and an increase in the plasma levels of plasmin and D-
dimer.22 Briel concluded that MS, independent of CPB, causes
both platelet dysfunction, and increased ﬁbrinolysis.3 In-
creasing postoperating bleeding, surgical re-exploration and
transfusion volume reﬂect a signiﬁcant statistical differences
between two groups and in other hand, the percentage change
of BT in group A was signiﬁcantly longer than to group B.
Mechanisms of postoperative bleeding in cardiac and non-
cardiac surgery are completely different.23 Low dose of MS
(<2 g) without affecting BT with vasodilatation and reducing
venous bleeding reduce total postoperative blood loss. But
larger dose of MS in cardiac surgery not only causes
tachycardia and venous dilatation but also leads to excessive
postoperative bleeding with increasing BT.22 We found that
hemodynamic changes of MS use are moderate hypotension
and tachycardia that lasted for a short period and resolved
spontaneously. Reducing blood loss in surgical ﬁeld provides
a better surgical ﬁeld, in noncardiac surgery which is different
in OPCAB surgery operations.23 Contrary to our results,
Dabbagh et al. demonstrated that less postoperative bleedingand packed cell use in the MS group were observed in elective
on-pump CABG surgery.24
5. Conclusions
These data indicate that however surgical and anesthesia
times were not different between two groups, but postopera-
tive diffuse bleeding was statistically different between two
groups. This difference reveals a coagulopathy of MS that was
not observed in group B. Platelet incorporation of MS at levels
attained with preoperative IV supplementation is associated
with inhibition of platelet aggregation through a PKC-
dependent mechanism. These observations may represent
one detrimental mechanism for the observed effect of MS in
postoperative bleeding.
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